Showing results (21-30 of 5,585) with videos related to

Sort By:
Pageof 559
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myelomaS V Rajkumar, R Fonseca, M Q Lacy, et al.
Oncology (Williston Park, N.Y.)|February 24, 2001
Thalidomide in multiple myelomaS V Rajkumar
Expert Review of Anticancer Therapy|July 13, 2002
Thalidomide in the treatment of multiple myelomaS V Rajkumar
Leukemia|January 10, 2014
Inhibitor of apoptosis proteins as therapeutic targets in multiple myelomaV Ramakrishnan, U Painuly, T Kimlinger, et al.
Oncology (Williston Park, N.Y.)|August 14, 2001
Current status of thalidomide in the treatment of cancerS V Rajkumar
Leukemia|August 2, 2001
Thalidomide for previously untreated indolent or smoldering multiple myelomaS V Rajkumar, A Dispenzieri, R Fonseca, et al.
Leukemia|August 21, 2012
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myelomaT E Witzig, K M Laumann, M Q Lacy, et al.
American Journal of Hematology|January 5, 2002
Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantationS V Rajkumar, R Fonseca, A Dispenzieri, et al.
Bone Marrow Transplantation|July 22, 1999
Autologous stem cell transplantation for relapsed and primary refractory myelomaS V Rajkumar, R Fonseca, M Q Lacy, et al.
Bone Marrow Transplantation|July 22, 1999
Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myelomaS V Rajkumar, R Fonseca, M Q Lacy, et al.
Pageof 559